Evidence map›Paper›PMID 33640980›Full record

ArticleJournal of industrial microbiology & biotechnology2021

Anti-cryptococcal activity of preussolides A and B, phosphoethanolamine-substituted 24-membered macrolides, and leptosin C from coprophilous isolates of Preussia typharum.

Bruno Perlatti, Nan Lan, Meichun Xiang, Cody E Earp, Joseph E Spraker, Colin J B Harvey, Connie B Nichols, J Andrew Alspaugh, James B Gloer, Gerald F Bills

Open access · goldAbstract read
In one paragraph

Article in Journal of industrial microbiology & biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Searching for new antifungals for the treatment of cryptococcosis.Revista da Sociedade Brasileira de Medicina Tropical · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Bruno PerlattiTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77054, USA.
Nan LanTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77054, USA.
Meichun XiangState Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, No. 3 Park 1, Beichen West Road, Chaoyang District, Beijing 100101, China.
Cody E EarpDepartment of Chemistry, University of Iowa, Iowa City, IA 52242, USA.
Joseph E SprakerHexagon Bio, Menlo Park, CA 94025, USA.
Colin J B HarveyHexagon Bio, Menlo Park, CA 94025, USA.
Connie B NicholsDepartments of Medicine and Molecular Genetics & Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
J Andrew AlspaughDepartments of Medicine and Molecular Genetics & Microbiology, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-3009-627X
James B GloerDepartment of Chemistry, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0002-9261-7571
Gerald F BillsTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77054, USA.ORCID 0000-0003-2352-8417
Brown Foundation · USDuke University · USMenlo School · USUniversity of Iowa · USChinese Academy of Sciences · CN

Funding

Mining the Coprophilous Mycobiome for New Cryptococcus Antiinfectives and Antifungal SynergistsR01GM121458 · NIGMS · UNIVERSITY OF IOWA · PI ALSPAUGH, ANDREW, AN, ZHIQIANG · 2017 to 2020
$2.1M
Chinese Scholarship CouncilKay and Ben Fortson EndowmentNIGMS NIH HHS R01 GM121458NIH HHS R01 GM121458
6 · The paper itself

Abstract

Cryptococcus neoformans is a serious human pathogen with limited options for treatment. We have interrogated extracts from fungal fermentations to find Cryptococcus-inhibiting natural products using assays for growth inhibition and differential thermosensitivity. Extracts from fermentations of four fungal strains from wild and domestic animal dung from Arkansas and West Virginia, USA were identified as Preussia typharum. The extracts exhibited two antifungal regions. Purification of one region yielded new 24-carbon macrolides incorporating both a phosphoethanolamine unit and a bridging tetrahydrofuran ring. The structures of these metabolites were established mainly by analysis of high-resolution mass spectrometry and 2D NMR data. Relative configurations were assigned using NOESY data, and the structure assignments were supported by NMR comparison with similar compounds. These new metabolites are designated preussolides A and B. The second active region was caused by the cytotoxin, leptosin C. Genome sequencing of the four strains revealed biosynthetic gene clusters consistent with those known to encode phosphoethanolamine-bearing polyketide macrolides and the biosynthesis of dimeric epipolythiodioxopiperazines. All three compounds showed moderate to potent and selective antifungal activity toward the pathogenic yeast C. neoformans.

Indexed as

Cryptococcus neoformansMacrolidesAnimalsAntifungal AgentsAscomycotaEthanolaminesHumansIndole AlkaloidsAntifungal AgentsEthanolaminesIndole Alkaloidsleptosin CMacrolidesphosphorylethanolamineAntifungalCryptococcusEpipolythiodioxopiperazineEthanolamine phosphate transferasePolyketidesSporormiaceae

Identifiers

PMID33640980
PMCPMC8788809
OpenAlexW3135333277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.